Humacyte, Inc. Financing Cash Flow
Humacyte, Inc. (HUMA) reported Financing Cash Flow of $76.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Humacyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $53.53M, a 2371.33% increase year-over-year.
- Humacyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $23.32M, a 50.10% decline year-over-year.
- Humacyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $57.17M, a 12.09% increase year-over-year.
- Humacyte, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$44.59M, a 5352.18% decline year-over-year.
- Humacyte, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $61.49M, a 46.15% decline from fiscal 2024.
- Humacyte, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $114.18M, a 2433.46% increase from fiscal 2023.
- Humacyte, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $4.51M.
- Humacyte, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$1.45M, a 100.54% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $53.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $76.85M 10-Q · filed 2026-08-12 | $134.02M derived: sum of 3 quarters · filed 2026-08-12 | $89.43M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $23.32M 10-Q · filed 2026-05-13 | $80.49M derived: sum of 2 quarters · filed 2026-05-13 | $35.90M derived: sum of 3 quarters · filed 2026-05-13 | $38.07M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $57.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $12.58M derived: sum of 2 quarters · filed 2026-03-27 | $14.75M derived: sum of 3 quarters · filed 2026-08-12 | $61.49M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$44.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$42.42M derived: sum of 2 quarters · filed 2026-08-12 | $4.31M 10-Q · filed 2025-11-12 | $55.32M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $48.91M 10-Q · filed 2026-08-12 | $99.91M derived: sum of 3 quarters · filed 2026-08-12 | $100.76M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $46.74M 10-Q · filed 2026-05-13 | $97.75M derived: sum of 2 quarters · filed 2026-05-13 | $98.59M derived: sum of 3 quarters · filed 2026-05-13 | $98.13M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $51.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $51.85M derived: sum of 2 quarters · filed 2026-03-27 | $51.39M derived: sum of 3 quarters · filed 2026-03-27 | $114.18M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $849.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $382.00K derived: sum of 2 quarters · filed 2025-11-12 | $63.18M 10-Q · filed 2025-11-12 | $62.84M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $62.33M 10-Q · filed 2025-08-11 | $61.99M derived: sum of 3 quarters · filed 2025-08-11 | $61.23M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $62.80M 10-Q · filed 2025-05-13 | $62.46M derived: sum of 2 quarters · filed 2025-05-13 | $61.70M derived: sum of 3 quarters · filed 2025-05-13 | $67.71M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$335.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.10M derived: sum of 2 quarters · filed 2025-03-31 | $4.92M derived: sum of 3 quarters · filed 2025-03-31 | $4.51M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$764.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $5.25M derived: sum of 2 quarters · filed 2024-11-08 | $4.84M 10-Q · filed 2024-11-08 | $4.63M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $6.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $5.61M 10-Q · filed 2024-08-13 | $5.39M derived: sum of 3 quarters · filed 2024-08-13 | $5.11M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | -$409.00K 10-Q · filed 2024-05-13 | -$621.00K derived: sum of 2 quarters · filed 2024-05-13 | -$910.00K derived: sum of 3 quarters · filed 2024-05-13 | -$1.39M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$212.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$501.00K derived: sum of 2 quarters · filed 2024-03-28 | -$985.00K derived: sum of 3 quarters · filed 2024-03-28 | -$1.45M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$773.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.23M 10-Q · filed 2023-11-09 | $5.31M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$484.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$945.00K 10-Q · filed 2023-08-14 | $5.60M derived: sum of 3 quarters · filed 2023-08-14 | $247.68M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$461.00K 10-Q · filed 2023-05-12 | $6.08M derived: sum of 2 quarters · filed 2023-05-12 | $248.17M derived: sum of 3 quarters · filed 2023-05-12 | $247.25M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $248.63M derived: sum of 2 quarters · filed 2023-03-24 | $247.71M derived: sum of 3 quarters · filed 2023-03-24 | $266.98M 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $242.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $241.17M derived: sum of 2 quarters · filed 2022-11-10 | $260.44M 10-Q · filed 2022-11-10 | $260.44M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$916.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $18.36M 10-Q · filed 2022-08-12 | -$95.14K 10-Q · filed 2021-08-16 | $18.36M derived: sum of 3 quarters · filed 2022-08-12 | $119.70M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $19.27M 10-Q · filed 2022-05-13 | -$87.96K 10-Q · filed 2021-05-17 | $19.28M derived: sum of 2 quarters · filed 2022-05-13 | $120.61M derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $6.06K derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | $101.34M 10-K/A · filed 2021-05-14 | $2.05M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $101.33M 10-Q · filed 2020-11-13 | $2.38M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |